|
Accueil > Actualité
Phaxiam: in receivership proceedings
(CercleFinance.com) - Phaxiam Therapeutics announces that, at its request, the Lyon Commercial Court decided on March 6, 2025 to open receivership proceedings.
In an extremely difficult financing environment for listed biotechs and small caps, and after several unsuccessful refinancing initiatives, the Company is unable to extend its cash horizon sufficiently, and finds itself in a financing impasse; the Company is therefore obliged to place itself under the protection of the Lyon Commercial Court. The Company will continue to operate during the observation period, in accordance with legal provisions. Regular press releases will be issued as the proceedings progress. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
30/05/2025 18:02
GE HealthCarede nouvelles directives recommandent Cerianna 30/05/2025 17:37 Aker Solutionscontrat de 2 GW pour BalWin2 en Allemagne 30/05/2025 17:08 Netflixle titre surperforme, BofA en renfort 30/05/2025 16:35 Pfizerla mortalité d'un cancer colorectal divisée par deux 30/05/2025 16:24 Alstomextension de la ligne 1 du métro de Kanpur, en Inde 30/05/2025 16:05 Solariasoutenu par un relèvement de broker Tous les articles sociétés |
